LeMaitre Vascular (LMAT)
(Delayed Data from NSDQ)
$85.01 USD
-1.24 (-1.44%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $84.81 -0.20 (-0.24%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth C Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
LMAT 85.01 -1.24(-1.44%)
Will LMAT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for LMAT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LMAT
LeMaitre Vascular (LMAT) Surpasses Q2 Earnings and Revenue Estimates
HLN vs. LMAT: Which Stock Is the Better Value Option?
LMAT: What are Zacks experts saying now?
Zacks Private Portfolio Services
HLN vs. LMAT: Which Stock Should Value Investors Buy Now?
Merit Medical (MMSI) Hits 52-Week High: What's Aiding It?
Glaukos (GKOS) Reaches 52-Week High: What's Driving the Stock?
Other News for LMAT
LeMaitre price target raised by $18 at Stifel, here's why
Buy Rating Affirmed for Lemaitre Vascular Amid Strong Fiscal Performance and Growth Prospects
LeMaitre price target raised by $13 at Barrington, here's why
Lemaitre Vascular: A Strong Buy on Sustained Growth and Strategic Acquisitions
Stifel Nicolaus Reaffirms Their Buy Rating on Lemaitre Vascular (LMAT)